News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
Discover Latest #Ulcer News, Articles and Videos with Contenting
Sore Mouth or Ulcer in Cats Sore mouth or ulcer in cats is a common problem. Symptoms can range from redness of the gums to ulceration of the gums and mouth. Oral ulcers can be caused by a number of things, including dental disease, tumors, infections, trauma, and other ailments. If your cat is displaying any of these signs, it’s important to take your pet to the vet. Your vet can help you determine the cause of the sore mouth or ulcer and provide the best treatment. Gastric Ulcer Treatment Gastric ulcers are a common condition in cats and can be caused by a variety of factors, including stress, bacterial infections, and medications. Treatment for gastric ulcers depends on the underlying cause. Your veterinarian may prescribe antibiotics, anti-inflammatory drugs, or antacid medications to reduce the acidity in the stomach. In some cases, surgery may be recommended to remove any tumors or foreign objects that may be causing the ulcer. Dental Ulcer Treatment Dental ulcers are caused by a variety of factors, including dental disease, trauma, and infections. Treatment for dental ulcers will depend on the underlying cause
Frontiers | Clinical implantation of 92 VACStents in the upper gastrointestinal tract of 50 patients—applicability and safety analysis of an innovative endoscopic concept
Endoscopic vacuum therapy (EVT) as novel treatment option for upper gastrointestinal wall defects is based on the principles of evacuation of secretions, removal of wound debris, and finally containment of defects improving the clinical outcome in the last decade. Covered stents however are hampered by a high rate of migration and missing functional drainage, whereas endoluminal EVT devices are limited by obstruction of the GI tract. The innovative design of the VACStent consists of a fully covered Nitinol-stent within a polyurethane-sponge cylinder, allowing EVT while stent passage is still open. The clinical experience of three different prospective study cohorts is analyzed regarding safe practicality (positioning, release of the stent), complete leak coverage and effective suction-treatment of esophageal leaks. Task of this study was to pool the data to get a broader base for analysis. In total, trans-nasal derivation of the catheter, suction and drainage of secretion via vacuum pump were performed without any adversity. In the pooled Study cohort of 92 VACStent applications, the mean stent indwelling time was 5.2 days (range 2-8 days) without any dislocation of the device. Removal of the VACStent was done without complication, in one case the sponge was lost but subsequently fully preserved. Minor local erosions and bleeding and one subsequent hemostasis were recorded unfrequently during withdrawal of the device (5.4 %, 5/92) but no perforation or pressure ulcer. Despite a high heterogeneity regarding primary disease and pretreatments a cure rate of 76 % (38/50 patients) could be achieved. In summary, insertion and release procedure was regarded as easy and simple with a low potential of dislocation. The VACStent was well tolerated by the patient while keeping the drainage function of the sponge achieving directly a wound closure by continuous suction and improving the healing process. The application of the VACStent offers a promising new option for improved clinical treatment in various indications of the upper gastrointestinal wall, which should be validated in larger clinical studies.
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance | Annals of the Rheumatic Diseases
Objectives Based on primary results from ORAL Surveillance, an event-driven clinical trial of risk-enriched patients, identify subpopulations with different relative risk (ie, ‘high-risk’ and ‘low-risk’) with tofacitinib versus tumour necrosis factor inhibitors (TNFi). Methods Patients with rheumatoid arthritis aged ≥50 years with ≥1 additional cardiovascular risk factor received tofacitinib 5 or 10 mg two times a day or TNFi. Prior analyses had identified age and smoking as risk factors of particular interest across safety outcomes. Hazard ratios (HRs) and incidence rates were evaluated by age and smoking individually and in combination. Results were validated across tofacitinib development programmes. Results ‘Age ≥65 years or ever smoker’ defined a group (‘high-risk’) with increased risk of malignancies (excluding non-melanoma skin cancer), major adverse cardiovascular events, myocardial infarction, venous thromboembolism and all-cause death with tofacitinib (combined doses) versus TNFi (HRs 1.41–5.19). In patients ‘aged <65 years and never smokers’ (’low-risk’), there was no detectable risk increase with tofacitinib versus TNFi (HRs ≈1.0) up to 6 years of follow-up, and absolute risk remained low and was corroborated across tofacitinib rheumatoid arthritis, psoriatic arthritis and ulcerative colitis programmes with up to 10 years of observation. Conclusions This posthoc analysis of ORAL Surveillance identified two tofacitinib subpopulations with different relative risk versus TNFi. High risk was confined to patients defined by distinct risk factors age ≥65 years or smoking, and these differentiating risk factors accounted for the excess risk observed with tofacitinib versus TNFi. These findings can guide individualised benefit/risk assessment and clinical decision-making on treatment with tofacitinib. Trial registration numbers [NCT02092467][1], [NCT01262118][2], [NCT01484561][3], [NCT00147498][4], [NCT00413660][5], [NCT00550446][6], [NCT00603512][7], [NCT00687193][8], [NCT01164579][9], [NCT00976599][10], [NCT01059864][11], [NCT01359150][12], [NCT02147587][13], [NCT00960440][14], [NCT00847613][15], [NCT00814307][16], [NCT00856544][17], [NCT00853385][18], [NCT01039688][19], [NCT02281552][20], [NCT02187055][21], [NCT02831855][22], [NCT00413699][23], [NCT00661661][24], [NCT00787202][25], [NCT01465763][26], [NCT01458951][27], [NCT01458574][28], [NCT01470612][29], [NCT01877668][30], [NCT01882439][31], [NCT01976364][32]. Data are available on reasonable request. On request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual deidentified participant data. See <https://www.pfizer.com/science/clinical-trials/trial-data-and-resultsformoreinformation>. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT02092467&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01262118&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [3]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01484561&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [4]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00147498&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [5]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00413660&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [6]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00550446&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [7]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00603512&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [8]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00687193&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [9]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01164579&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [10]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00976599&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [11]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01059864&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [12]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01359150&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [13]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT02147587&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [14]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00960440&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [15]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00847613&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [16]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00814307&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [17]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00856544&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [18]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00853385&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [19]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01039688&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [20]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT02281552&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [21]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT02187055&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [22]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT02831855&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [23]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00413699&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [24]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00661661&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [25]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00787202&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [26]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01465763&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [27]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01458951&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [28]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01458574&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [29]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01470612&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [30]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01877668&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [31]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01882439&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom [32]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01976364&atom=%2Fannrheumdis%2Fearly%2F2023%2F05%2F04%2Fard-2022-223715.atom
DR ELLIE CANNON: My GP tells me I must live with my swollen, red legs at age 90. Is she right? - Sound Health and Lasting Wealth
For a good six months I have had swollen legs. At times they've been red, hot and very painful. I'm 90 and I've been prescribed antibiotics twice, but they didn't help. Most recently my GP said I had to learn to live with it. Is she right?Leg swelling, wounds and ulcers that are slow to
Woman with diabetic foot ulcer and osteomyelitis successfully treated with ayurvedic treatment: case report
Rajasthan: Diabetic foot ulcer (DFU) with osteomyelitis is a devastating condition which frequently requires surgery to remove the infected and necrosed bone and soft tissues. Most cases result in...
Dermatology Advisor - Skin Cancer, Acne, Skin Injury | Dermatology News, Treatment Studies
01.06.2023
Black Patients Hospitalized With Skin Ulcers Have Greater Length of Stay
There may be racial and ethnic differences in skin ulcer hospitalizations, with Black patients experiencing greater lengths of stays and charges.